Invivyd (NASDAQ:IVVD) Announces Earnings Results, Beats Expectations By $0.01 EPS

Key Points

• Invivyd reported a quarterly loss of $0.14 per share, beating analyst expectations by $0.01, while revenue of $14.29 million fell slightly short of the $14.40 million consensus estimate.
• The stock declined to $0.69 during Thursday trading and remains near its 52-week low, with a market capitalization of approximately $202 million and continued negative profitability metrics.
• Analyst sentiment is mixed, resulting in a consensus “Hold” rating and an $8.00 target price; institutional investors own about 70.36% of the company’s shares.

Invivyd (NASDAQ:IVVD - Get Free Report) released its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.01, FiscalAI reports. The company had revenue of $14.29 million during the quarter, compared to analysts' expectations of $14.40 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%.

Invivyd Price Performance

NASDAQ:IVVD traded down $0.05 during midday trading on Thursday, hitting $0.69. The company's stock had a trading volume of 1,975,083 shares, compared to its average volume of 3,107,846. Invivyd has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm has a market cap of $202.01 million, a P/E ratio of -2.21 and a beta of 0.71. The firm's 50 day moving average is $0.79 and its 200-day moving average is $1.26.

Analyst Ratings Changes

IVVD has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research reissued a "buy" rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen downgraded Invivyd from a "hold" rating to a "strong sell" rating in a research report on Saturday, May 16th. Finally, HC Wainwright restated a "buy" rating and issued a $10.00 target price on shares of Invivyd in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Invivyd presently has a consensus rating of "Hold" and a consensus target price of $8.00.

Institutional Trading of Invivyd

Several large investors have recently made changes to their positions in IVVD. Janus Henderson Group PLC increased its stake in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company's stock worth $80,870,000 after acquiring an additional 7,160,065 shares during the period. RA Capital Management L.P. acquired a new position in Invivyd during the third quarter valued at $18,831,000. ADAR1 Capital Management LLC purchased a new stake in Invivyd in the third quarter valued at $8,108,000. Vanguard Group Inc. boosted its holdings in Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company's stock valued at $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. Finally, State Street Corp boosted its holdings in Invivyd by 1,636.7% in the fourth quarter. State Street Corp now owns 5,637,593 shares of the company's stock valued at $13,925,000 after purchasing an additional 5,312,986 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source